Rilpivirine as a potential candidate for the treatment of HIV-associated neurocognitive disorders (HAND).

Szczegóły
Abstrakt

Tytuł:: Rilpivirine as a potential candidate for the treatment of HIV-associated neurocognitive disorders (HAND).
Autorzy:: Ntshangase S; Catalysis and Peptide Research Unit, University of KwaZulu-Natal, Westville Campus, E-block, 6th floor, Room E1-06-016, Durban, South Africa.
Mdanda S; Catalysis and Peptide Research Unit, University of KwaZulu-Natal, Westville Campus, E-block, 6th floor, Room E1-06-016, Durban, South Africa.
Naicker T; Catalysis and Peptide Research Unit, University of KwaZulu-Natal, Westville Campus, E-block, 6th floor, Room E1-06-016, Durban, South Africa.
Kruger HG; Catalysis and Peptide Research Unit, University of KwaZulu-Natal, Westville Campus, E-block, 6th floor, Room E1-06-016, Durban, South Africa.
Govender T; Catalysis and Peptide Research Unit, University of KwaZulu-Natal, Westville Campus, E-block, 6th floor, Room E1-06-016, Durban, South Africa.
Baijnath S; Catalysis and Peptide Research Unit, University of KwaZulu-Natal, Westville Campus, E-block, 6th floor, Room E1-06-016, Durban, South Africa. .
Źródło:: Journal of molecular histology [J Mol Histol] 2019 Aug; Vol. 50 (4), pp. 295-303. Date of Electronic Publication: 2019 Apr 22.
Typ publikacji:: Journal Article
Język:: English
Imprint Name(s):: Publication: Dordrecht, The Netherlands : Springer Netherlands
Original Publication: Dordrecht, The Netherlands : Kluwer Academic Publishers, 2004-
MeSH Terms:: Brain/*metabolism
HIV Infections/*complications
Neurocognitive Disorders/*etiology
Rilpivirine/*therapeutic use
Animals ; Blood-Brain Barrier/metabolism ; Chromatography, Liquid ; Female ; HIV Infections/drug therapy ; Humans ; Neurocognitive Disorders/virology ; Rats ; Rats, Sprague-Dawley ; Reverse Transcriptase Inhibitors/blood ; Reverse Transcriptase Inhibitors/pharmacokinetics ; Reverse Transcriptase Inhibitors/therapeutic use ; Rilpivirine/analysis ; Rilpivirine/blood ; Rilpivirine/pharmacokinetics ; Tandem Mass Spectrometry
References:: Phys Med Biol. 2000 Jul;45(7):2011-27. (PMID: 10943935)
Hepatology. 2002 Jan;35(1):182-9. (PMID: 11786975)
Clin Infect Dis. 2004 May 1;38(9):1311-6. (PMID: 15127346)
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15647-52. (PMID: 16227428)
Drug Discov Today. 2005 Oct 15;10(20):1357-67. (PMID: 16253874)
AIDS. 2006 Apr 4;20(6):879-87. (PMID: 16549972)
Lancet. 1991 May 11;337(8750):1119-21. (PMID: 1674013)
Expert Opin Drug Saf. 2007 Mar;6(2):147-54. (PMID: 17367260)
Arch Neurol. 2008 Jan;65(1):65-70. (PMID: 18195140)
Behav Brain Res. 2008 Apr 9;188(2):337-47. (PMID: 18242723)
Cancer Res. 1990 Sep 1;50(17 Suppl):5618S-5627S. (PMID: 2167158)
Lancet. 2011 Jul 16;378(9787):238-46. (PMID: 21763936)
Cereb Cortex. 2012 Sep;22(9):2065-75. (PMID: 22016479)
BMC Infect Dis. 2011 Dec 28;11:356. (PMID: 22204557)
Biochem Pharmacol. 2012 Aug 1;84(3):241-8. (PMID: 22504027)
Biomed Chromatogr. 2013 Feb;27(2):172-8. (PMID: 22729755)
J Proteomics. 2012 Aug 30;75(16):4999-5013. (PMID: 22842290)
J Med Invest. 2013;60(1-2):35-40. (PMID: 23614909)
Patient Prefer Adherence. 2013 Jun 19;7:531-42. (PMID: 23814462)
Antimicrob Agents Chemother. 2013 Oct;57(10):5067-79. (PMID: 23917319)
J Int AIDS Soc. 2013 Sep 04;16:1-14. (PMID: 24008177)
Antimicrob Agents Chemother. 2015 Feb;59(2):960-71. (PMID: 25421485)
Assay Drug Dev Technol. 2015 Jun;13(5):277-84. (PMID: 26070010)
J Mol Histol. 2015 Oct;46(4-5):439-42. (PMID: 26208572)
Anal Chem. 2016 Apr 19;88(8):4346-53. (PMID: 27014927)
J Chromatogr B Analyt Technol Biomed Life Sci. 2016 Aug 1;1027:174-80. (PMID: 27290668)
Xenobiotica. 2018 Sep;48(9):938-944. (PMID: 28859520)
J Chromatogr B Analyt Technol Biomed Life Sci. 2019 Mar 15;1110-1111:116-123. (PMID: 30802754)
Neurology. 1993 Oct;43(10):2099-104. (PMID: 8413973)
Acta Neuropathol. 1993;85(2):185-9. (PMID: 8442409)
Contributed Indexing:: Keywords: Central nervous system; Drug distribution; Mass spectrometry imaging; Rilpivirine
Substance Nomenclature:: 0 (Reverse Transcriptase Inhibitors)
FI96A8X663 (Rilpivirine)
Entry Date(s):: Date Created: 20190424 Date Completed: 20200106 Latest Revision: 20200225
Update Code:: 20240105
DOI:: 10.1007/s10735-019-09826-y
PMID:: 31011919
: Czasopismo naukowe

Full Text Finder

As the HIV epidemic continues to contribute to global morbidity and mortality, the prevalence of HIV-associated neurological disorders (HAND) also continues to be a major concern in infected individuals, despite the widespread use of combination antiretroviral therapy. Therefore, current antiretroviral drugs should be able to reach therapeutic levels in the brain for the treatment of HAND. The brain distribution of the next-generation non-nucleoside reverse transcriptase inhibitor, rilpivirine (RPV) was investigated in healthy female Sprague-Dawley (SD) rats. The presented study involves the use of liquid chromatography-tandem mass spectrometry (LC-MS/MS) to estimate the concentrations of RPV in plasma and brain homogenate samples. The use of matrix-assisted laser desorption/ionization mass spectrometry imaging (MALDI-MSI) provided regional spatial distribution of RPV in brain tissue sections. The localization of RPV was found to be relatively high in the hypothalamus, thalamus and corpus callosum, brain regions known to be associated with neurodegeneration during HAND (including the cerebral cortex). This study has shown that RPV has an excellent blood-brain barrier penetrability. Thus, in combination with other antiretroviral drugs, better central nervous system (CNS) protection against HAND can possibly be achieved.

Informacja